Affimed N.V. (AFMD)
After hours:
| Previous Close | 1.2800 |
| Open | 1.2800 |
| Bid | 1.2100 x 3100 |
| Ask | 1.2400 x 4000 |
| Day's Range | 1.1900 - 1.2800 |
| 52 Week Range | 1.0300 - 5.1000 |
| Volume | |
| Avg. Volume | 2,131,978 |
| Market Cap | 143.756M |
| Beta (5Y Monthly) | 2.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5970 |
| Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.80 |
- GlobeNewswire
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
AFM13 combination with Artiva’s AB-101 NK cells: Received written feedback to pre-investigational new drug (IND) meeting request which supports plan for IND filing in H1 2023 and initiation of clinical study during 2023AFM24: Data updates from the three AFM24 ongoing studies are expected at scientific conferences in Q2/Q3 2023AFM28: Clinical trial application (CTA) cleared in France and Spain with additional filings in European countries pending; initiation of phase 1 study is expected in Q2 202
- Simply Wall St.
Investors in Affimed (NASDAQ:AFMD) have unfortunately lost 80% over the last year
Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...
- GlobeNewswire
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of AFM28 clinical development in the first half of 2023 on track HEIDELBERG, Germany, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced to
